Kingworld Medicines Group (HKSE:01110) EBIT : HK$115 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Kingworld Medicines Group EBIT?

Kingworld Medicines Group's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was HK$42 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$115 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kingworld Medicines Group's annualized ROC % for the quarter that ended in Dec. 2023 was 0.68%. Kingworld Medicines Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 21.12%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Kingworld Medicines Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 21.96%.

Kingworld Medicines Group EBIT Historical Data

The historical data trend for Kingworld Medicines Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kingworld Medicines Group EBIT Chart

Kingworld Medicines Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

94.91

102.01

99.45

89.20

115.29

Kingworld Medicines Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial															40.39	59.65	32.37	73.41	41.88

Competitive Comparison of Kingworld Medicines Group's EBIT

For the Pharmaceutical Retailers subindustry, Kingworld Medicines Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kingworld Medicines Group's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Kingworld Medicines Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kingworld Medicines Group's EV-to-EBIT falls into.

Kingworld Medicines Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$115 Mil.

Kingworld Medicines Group (HKSE:01110) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kingworld Medicines Group's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	20.414 * ( 1 - 61.65% )	/	( (1193.619	+	1105.721)	/ 2 )
=	7.828769	/	1149.67
=	0.68 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1498.247	-	241.401	-	( 296.477	-	max(0, 638.687	-	701.914	+	296.477	))
=	1193.619

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1463.093	-	220.558	-	( 212.225	-	max(0, 507.002	-	643.816	+	212.225	))
=	1105.721

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Kingworld Medicines Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	83.762	/	( ( (371.204 + max(-71.269, 0))	+	(421.889 + max(-2.812, 0)) )	/	2 )
=	83.762	/	( ( 371.204	+	421.889 )	/	2 )
=	83.762	/	396.5465
=	21.12 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(98.778	+	99.853	+	48.826)	-	(241.401	+	0	+	77.325)
=	-71.269

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(128.779	+	128.659	+	30.152)	-	(220.558	+	0	+	69.844)
=	-2.812

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kingworld Medicines Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	115.29	/	524.946
	=	21.96 %

Kingworld Medicines Group EBIT Related Terms

Thank you for viewing the detailed overview of Kingworld Medicines Group's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Kingworld Medicines Group (HKSE:01110) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Kingworld Medicines Group Ltd (HKSE:01110) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

198 Daxin Road, 8th-9th Floor, Block A, Majialong Chuangxin Building, Nanshan District, Guangdong Province, Shenzhen, CHN, 518016

Website

https://www.kingworld.com.cn

Kingworld Medicines Group Ltd is engaged in Distribution sales of pharmaceutical and healthcare products such as branded imported pharmaceutical and healthcare products primarily in Hong Kong and the PRC, and Manufacturing and sales of electrotherapeutic and physiotherapeutic devices and general medical examination devices primarily carried out in the PRC. It derives the majority of its revenue from Distribution sales of pharmaceutical and healthcare products segment.

Executives

Chan Lok San	2101 Beneficial owner
Zhao Li Sheng	2101 Beneficial owner
Sinopharm Capital Limited	2201 Interest of corporation controlled by you
Sinopharm Healthcare Fund L.p.	2101 Beneficial owner
Sun Hill Capital Investments Limited	2201 Interest of corporation controlled by you
Wu Aimin	2201 Interest of corporation controlled by you
Sun Hill Capital Investments Limited	2201 Interest of corporation controlled by you
Wu Aimin	2201 Interest of corporation controlled by you

Kingworld Medicines Group (HKSE:01110) Headlines

No Headlines